EP1024745A4 - Systeme de prelevement et de detection d'echantillons pour l'analyse d'haleine - Google Patents
Systeme de prelevement et de detection d'echantillons pour l'analyse d'haleineInfo
- Publication number
- EP1024745A4 EP1024745A4 EP98953727A EP98953727A EP1024745A4 EP 1024745 A4 EP1024745 A4 EP 1024745A4 EP 98953727 A EP98953727 A EP 98953727A EP 98953727 A EP98953727 A EP 98953727A EP 1024745 A4 EP1024745 A4 EP 1024745A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- breath
- passageway
- valve
- exhaled
- volume
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 238000001514 detection method Methods 0.000 title claims abstract description 9
- 238000004458 analytical method Methods 0.000 title description 11
- 238000005259 measurement Methods 0.000 claims description 14
- 238000000034 method Methods 0.000 claims description 14
- 239000000470 constituent Substances 0.000 claims description 4
- 230000008569 process Effects 0.000 claims description 3
- 239000000463 material Substances 0.000 claims description 2
- 230000000977 initiatory effect Effects 0.000 claims 2
- FGUUSXIOTUKUDN-IBGZPJMESA-N C1(=CC=CC=C1)N1C2=C(NC([C@H](C1)NC=1OC(=NN=1)C1=CC=CC=C1)=O)C=CC=C2 Chemical compound C1(=CC=CC=C1)N1C2=C(NC([C@H](C1)NC=1OC(=NN=1)C1=CC=CC=C1)=O)C=CC=C2 FGUUSXIOTUKUDN-IBGZPJMESA-N 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 abstract description 14
- OFBQJSOFQDEBGM-UHFFFAOYSA-N Pentane Chemical compound CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 10
- 238000012360 testing method Methods 0.000 description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 210000000496 pancreas Anatomy 0.000 description 6
- 208000035475 disorder Diseases 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 238000001871 ion mobility spectroscopy Methods 0.000 description 5
- 210000004185 liver Anatomy 0.000 description 5
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 4
- 239000007789 gas Substances 0.000 description 4
- 239000001257 hydrogen Substances 0.000 description 4
- 229910052739 hydrogen Inorganic materials 0.000 description 4
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 3
- 229910002092 carbon dioxide Inorganic materials 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 210000004072 lung Anatomy 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 description 2
- LSDPWZHWYPCBBB-UHFFFAOYSA-N Methanethiol Chemical compound SC LSDPWZHWYPCBBB-UHFFFAOYSA-N 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 239000001569 carbon dioxide Substances 0.000 description 2
- 208000019425 cirrhosis of liver Diseases 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 210000000936 intestine Anatomy 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 230000035764 nutrition Effects 0.000 description 2
- 150000002894 organic compounds Chemical class 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000029058 respiratory gaseous exchange Effects 0.000 description 2
- 238000005070 sampling Methods 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- FQZYTYWMLGAPFJ-OQKDUQJOSA-N tamoxifen citrate Chemical compound [H+].[H+].[H+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 FQZYTYWMLGAPFJ-OQKDUQJOSA-N 0.000 description 2
- BKAJNAXTPSGJCU-UHFFFAOYSA-N 4-methyl-2-oxopentanoic acid Chemical compound CC(C)CC(=O)C(O)=O BKAJNAXTPSGJCU-UHFFFAOYSA-N 0.000 description 1
- GWSYFJYNPFZEQZ-UHFFFAOYSA-N 5-methyl-n-(5-methyl-2-propan-2-ylcyclohexyl)-2-propan-2-ylcyclohexan-1-amine Chemical compound CC(C)C1CCC(C)CC1NC1C(C(C)C)CCC(C)C1 GWSYFJYNPFZEQZ-UHFFFAOYSA-N 0.000 description 1
- 206010003645 Atopy Diseases 0.000 description 1
- 102100026189 Beta-galactosidase Human genes 0.000 description 1
- 206010006326 Breath odour Diseases 0.000 description 1
- 201000003883 Cystic fibrosis Diseases 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- OTMSDBZUPAUEDD-UHFFFAOYSA-N Ethane Chemical compound CC OTMSDBZUPAUEDD-UHFFFAOYSA-N 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 208000007882 Gastritis Diseases 0.000 description 1
- 108010007979 Glycocholic Acid Proteins 0.000 description 1
- 208000032139 Halitosis Diseases 0.000 description 1
- 241000590002 Helicobacter pylori Species 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010061216 Infarction Diseases 0.000 description 1
- 108010059881 Lactase Proteins 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 1
- 206010067125 Liver injury Diseases 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 206010025476 Malabsorption Diseases 0.000 description 1
- 208000004155 Malabsorption Syndromes Diseases 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 208000012868 Overgrowth Diseases 0.000 description 1
- 208000008469 Peptic Ulcer Diseases 0.000 description 1
- 208000028017 Psychotic disease Diseases 0.000 description 1
- 208000034189 Sclerosis Diseases 0.000 description 1
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- UCKMPCXJQFINFW-UHFFFAOYSA-N Sulphide Chemical compound [S-2] UCKMPCXJQFINFW-UHFFFAOYSA-N 0.000 description 1
- XSQUKJJJFZCRTK-NJFSPNSNSA-N UREA C 14 Chemical compound N[14C](N)=O XSQUKJJJFZCRTK-NJFSPNSNSA-N 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000016383 Zea mays subsp huehuetenangensis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 239000003463 adsorbent Substances 0.000 description 1
- 230000000274 adsorptive effect Effects 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 229960000212 aminophenazone Drugs 0.000 description 1
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 1
- 108010005774 beta-Galactosidase Proteins 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- JFVVHGLWMZEUQM-UHFFFAOYSA-N butan-2-one;propan-1-ol Chemical compound CCCO.CCC(C)=O JFVVHGLWMZEUQM-UHFFFAOYSA-N 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000007882 cirrhosis Effects 0.000 description 1
- WSVCVAZKQUJHGQ-UHFFFAOYSA-N copper ethane Chemical compound [Cu].CC WSVCVAZKQUJHGQ-UHFFFAOYSA-N 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 239000002360 explosive Substances 0.000 description 1
- XUFQPHANEAPEMJ-UHFFFAOYSA-N famotidine Chemical compound NC(N)=NC1=NC(CSCCC(N)=NS(N)(=O)=O)=CS1 XUFQPHANEAPEMJ-UHFFFAOYSA-N 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 238000004817 gas chromatography Methods 0.000 description 1
- RFDAIACWWDREDC-FRVQLJSFSA-N glycocholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 RFDAIACWWDREDC-FRVQLJSFSA-N 0.000 description 1
- 231100001261 hazardous Toxicity 0.000 description 1
- 231100000234 hepatic damage Toxicity 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 230000007574 infarction Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 229940116108 lactase Drugs 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 229960004194 lidocaine Drugs 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 230000008818 liver damage Effects 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 235000009973 maize Nutrition 0.000 description 1
- 238000010339 medical test Methods 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 208000011906 peptic ulcer disease Diseases 0.000 description 1
- 238000005502 peroxidation Methods 0.000 description 1
- RCIMBBZXSXFZBV-UHFFFAOYSA-N piromidic acid Chemical compound N1=C2N(CC)C=C(C(O)=O)C(=O)C2=CN=C1N1CCCC1 RCIMBBZXSXFZBV-UHFFFAOYSA-N 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 239000000700 radioactive tracer Substances 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 201000000980 schizophrenia Diseases 0.000 description 1
- 229910052711 selenium Inorganic materials 0.000 description 1
- 239000011669 selenium Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 230000007863 steatosis Effects 0.000 description 1
- 231100000240 steatosis hepatitis Toxicity 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 150000003573 thiols Chemical class 0.000 description 1
- 229950000184 urea c 14 Drugs 0.000 description 1
- 239000012855 volatile organic compound Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/41—Detecting, measuring or recording for evaluating the immune or lymphatic systems
- A61B5/411—Detecting or monitoring allergy or intolerance reactions to an allergenic agent or substance
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/08—Measuring devices for evaluating the respiratory organs
- A61B5/097—Devices for facilitating collection of breath or for directing breath into or through measuring devices
Definitions
- the present invention relates generally to breath analyzer systems, and more particularly, to a novel breath analyzer system optimized for the detecting target compounds, e.g., related to specific bodily disorder.
- a breath analyzer system comprising a mask device for placement over a person's mouth for receiving that person's breath exhalations.
- An electronic sensor provided at a valve located at an entrance of a first outlet passageway initiates detection of breath exhalation and generates a control signal.
- a control device Upon receipt of the control signal, a control device initiates a breath volume measurement and collection cycle including directing a pre -determined volume of breath exhalation through the first passageway in a first part of the measurement cycle, and, directing the remaining portion of breath exhalation to a second passageway for receipt by a breath adsorbing media located in the second passageway during a second part of the measurement cycle.
- the first and second measurement cycles are repeated until a desired volume of exhaled breath has been sampled. Subsequently, the contents of the breath collected by the adsorbing media is analyzed by an ion mobility spectrometer or combination gas chromatographic GC/IMS device. BRIEF DESCRIPTION OF THE DRAWINGS
- Figure 1 is a diagram illustrating the breath analyzer system of the invention.
- the breath analyzer instrument of the instant invention implements the following basic methodology: 1) sample collection, 2) sample preparation, and 3) sample analysis.
- sample collection the device samples the breath of the patient and traps the organic compounds that are to be analyzed.
- the instrument 10 is designed to take into account the mechanics of breathing. For example, a standard 70 -kg adult at rest breathes about 7.5L/min. The cycle that is responsible for this process consists of four stages: (rest, during inspiration) , end inspiration (equilibrium) , (during expiration) , and (expiration) .
- tidal volume an amount of air that is moved in and out with each breath is called the tidal volume which is usually about 500 ml.
- the first 150 ml of every expiration consists of "dead space" air from upper airways, where no gas exchange has occurred. This volume is wasted since it does not participate in gas exchange in the lungs, consequently, is does not contain target compounds. This means that of every breath only about 350 ml of air is suitable for collection and analysis. Thus, for example, to determine how much of a sample to collect in order to detect a target compound with a concentration of 100 ppt, the total volume of usable air that must be collected has to be determined.
- the breath analysis device of the invention automatically collects the correct amount of usable air from the patient.
- FIG. 1 is schematic diagram depicting the the breath analyzer system 10 of the invention, including the mask component 12.
- the mask component 12 includes all the elements and on-board electronics 15 to carry out a pre-programmed sequence to efficiently collect the usable air as the patient breaths normally.
- the invention supports the following modes of operation: 1) Stand-by and 2) Collect Sample.
- Stand-by Mode the mask is either placed over the patient's face to receive breath exhalations, a sample "trap” is removed from the mask, or, the mask is removed from the patient's face.
- a collect sample mode of operation the specified volume of usable air as the patient breaths normally, is collected.
- the sample mask is provided with a first intake passageway 22, and outlet passageways 25, 30 and 35.
- the outlet passageway 30 includes a sample collection chamber 45 having media for collecting constituents of said exhaled breath.
- Three valves 101, 102 and 103 corresponding to respective passage ways 22, 25 and 30 which actuate in sequence with the in and out breathing of the patient are provided. For instance, during patient inhalation: valve 101 opens enabling the person to inhale via passageway 22, but valves 102-103 remain closed; during exhalation: valves 101 and 103 are closed, and valve 102 is open.
- the operational sequence is as follows: first, a start button 20 is selected to initiate an operation sequence that is executed by the on-board control microprocessor 50.
- the microprocessor specifically waits for a signal from an electronics sensor 40 attached to valve 102. As the patient exhales, valve 101 closes and the shunt valve 103 opens. A signal from the electronics sensor 40 is received by the microprocessor 50 to start the measuring sequence.
- the microprocessor directs valve 102 to close, and simultaneously, directs valve 103 to open to allow the remaining exhaled breath to pass through a sample trap 60.
- the trap 60 contains a suitable high surface area adsorbant material, e.g., hydrophobic adsorbent such as Tenax-polymeric.
- Flow sensor 70 measures the usable air volume.
- the microprocessor keeps an account of the total volume of usable air that passes through valve 103. When the appropriate volume has been expired (5000-10,000 ml), the microprocessor 50 closes valve 103 and signals that the process is finished. Valves 101 and 102 are now in the standby configuration.
- sample collector 60 including the adsorbed breath sample is removed, for example, by a robotic interface device, and is placed in an analyzer.
- the breath analyzer system 10 includes a modified GC/IMS based instrument 80 with a robotic interface to prepare sample traps for processing in a GC/IMS analytical device, which may comprise for example, a modified version of an ORION explosive detection system (manufactured by Intelligent Detection Systems, Inc., the assignee of the present invention), similar to the system described in U.S. Patent Nos. 5,189,301, 5,465,607 and 5,585,575, the contents and disclosure of each of which are incorporated by reference as if fully set forth herein.
- the modifications would include optimized analytical components to accommodate the various target compounds, a list of which may be found in Appendix A.
- the analysis time should not exceed 15 to 20 seconds.
- pancreas pancreas hydrogen after Perman,J.A. of damage/cys ic a dose of rice the John f ibrosis s rch Hopkins University School of Medicine (in Phillips 1992) other diseases pancreas IOC in 14C02 Phillips 1992 causi ng from a dose of pancreas radiol abeled dysfunction trig! yceride
- VSC Volatile sulfur halitosi s compounds
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medical Informatics (AREA)
- Molecular Biology (AREA)
- Veterinary Medicine (AREA)
- Biophysics (AREA)
- Pathology (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Public Health (AREA)
- Physics & Mathematics (AREA)
- Surgery (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Vascular Medicine (AREA)
- Physiology (AREA)
- Pulmonology (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measurement Of The Respiration, Hearing Ability, Form, And Blood Characteristics Of Living Organisms (AREA)
- Sampling And Sample Adjustment (AREA)
Abstract
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US6268397P | 1997-10-22 | 1997-10-22 | |
| US62683P | 1997-10-22 | ||
| PCT/US1998/022091 WO1999020177A1 (fr) | 1997-10-22 | 1998-10-20 | Systeme de prelevement et de detection d'echantillons pour l'analyse d'haleine |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| EP1024745A1 EP1024745A1 (fr) | 2000-08-09 |
| EP1024745A4 true EP1024745A4 (fr) | 2001-04-25 |
Family
ID=22044127
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EP98953727A Withdrawn EP1024745A4 (fr) | 1997-10-22 | 1998-10-20 | Systeme de prelevement et de detection d'echantillons pour l'analyse d'haleine |
Country Status (4)
| Country | Link |
|---|---|
| EP (1) | EP1024745A4 (fr) |
| JP (1) | JP2001520068A (fr) |
| CA (1) | CA2306760A1 (fr) |
| WO (1) | WO1999020177A1 (fr) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1217643B1 (fr) | 2000-12-15 | 2008-09-10 | V & F Analyse- und Messtechnik G.m.b.H. | Méthode et dispositif pour la détermination de l' état d'organismes et de produits naturels ainsi que pour l'analyse de mélanges gazeux comprenant des composantes principales et secondaires |
| GB2379612A (en) * | 2001-06-25 | 2003-03-19 | Desmond Bryan Mills | Face mask with respiratory gas tester |
| WO2008092198A1 (fr) * | 2007-01-31 | 2008-08-07 | Euan Roger Tovey | Dispositif de collecte permettant d'échantillonner des courants d'air exhalé |
| CN102415884A (zh) * | 2011-09-09 | 2012-04-18 | 北京大学深圳研究生院 | 一种压电薄膜传感器与无线呼吸检测电路的mcp封装形式 |
| US11166636B2 (en) * | 2018-02-20 | 2021-11-09 | Boston Scientific Scimed, Inc. | Breath sampling mask and system |
| WO2020081834A1 (fr) | 2018-10-19 | 2020-04-23 | Regents Of The University Of Minnesota | Systèmes et méthodes de détection d'une affection cérébrale |
| CN113747836A (zh) | 2019-04-29 | 2021-12-03 | 明尼苏达大学董事会 | 用于评估和治疗出血及其他病症的系统和方法 |
| US12178568B2 (en) * | 2020-08-03 | 2024-12-31 | Chia-Pin Liu | Sampling face mask |
| SE546321C2 (en) * | 2021-04-08 | 2024-10-01 | Pinsalus Ab | System for breath analysis comprising a breath sampling apparatus and a sample preparation apparatus |
| CN115350556A (zh) * | 2022-08-16 | 2022-11-18 | 苏州思萃同位素技术研究所有限公司 | Co2呼气试验中呼出co2的处置及回收方法和装置 |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4346584A (en) * | 1980-10-20 | 1982-08-31 | Boehringer John R | Gas analyzer |
| US4735777A (en) * | 1985-03-11 | 1988-04-05 | Hitachi, Ltd. | Instrument for parallel analysis of metabolites in human urine and expired air |
| JPH05329132A (ja) * | 1992-05-28 | 1993-12-14 | Anima Kk | ブレスバイブレス代謝測定装置 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3622278A (en) * | 1969-04-21 | 1971-11-23 | Hittman Associates Inc | Method and means for breath analysis |
| US3910261A (en) * | 1974-06-11 | 1975-10-07 | Bourns Inc | End-tidal gas analysis apparatus for respirators |
| JP3838671B2 (ja) * | 1993-10-25 | 2006-10-25 | アークレイ株式会社 | 呼気採取装置 |
| JPH07116145A (ja) * | 1993-10-25 | 1995-05-09 | Kyoto Daiichi Kagaku:Kk | 呼気採取装置 |
-
1998
- 1998-10-20 EP EP98953727A patent/EP1024745A4/fr not_active Withdrawn
- 1998-10-20 JP JP2000516590A patent/JP2001520068A/ja active Pending
- 1998-10-20 CA CA002306760A patent/CA2306760A1/fr not_active Abandoned
- 1998-10-20 WO PCT/US1998/022091 patent/WO1999020177A1/fr not_active Ceased
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4346584A (en) * | 1980-10-20 | 1982-08-31 | Boehringer John R | Gas analyzer |
| US4735777A (en) * | 1985-03-11 | 1988-04-05 | Hitachi, Ltd. | Instrument for parallel analysis of metabolites in human urine and expired air |
| JPH05329132A (ja) * | 1992-05-28 | 1993-12-14 | Anima Kk | ブレスバイブレス代謝測定装置 |
Non-Patent Citations (3)
| Title |
|---|
| MICHAEL PHILLIPS: "Breath Tests in Medicine", SCIENTIFIC AMERICAN, vol. 267, no. 1, July 1992 (1992-07-01), pages 52 - 57, XP002158968 * |
| PATENT ABSTRACTS OF JAPAN vol. 018, no. 157 (C - 1180) 16 March 1994 (1994-03-16) * |
| See also references of WO9920177A1 * |
Also Published As
| Publication number | Publication date |
|---|---|
| WO1999020177A1 (fr) | 1999-04-29 |
| CA2306760A1 (fr) | 1999-04-29 |
| EP1024745A1 (fr) | 2000-08-09 |
| JP2001520068A (ja) | 2001-10-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Guntner et al. | Breath sensors for health monitoring | |
| Phillips et al. | Ion-trap detection of volatile organic compounds in alveolar breath | |
| JP3838671B2 (ja) | 呼気採取装置 | |
| US5022406A (en) | Module for determining diffusing capacity of the lungs for carbon monoxide and method | |
| Schubert et al. | Breath analysis in critically ill patients: potential and limitations | |
| US8485984B2 (en) | Portable breath collection system for use in breath tests | |
| Salerno-Kennedy et al. | Potential applications of breath isoprene as a biomarker in modern medicine: a concise overview | |
| US5383469A (en) | Neonatal hemolysis detection using end-tidal breath sampler and analyzer apparatus | |
| Mukhopadhyay | Don't waste your breath | |
| JPH0554783B2 (fr) | ||
| JPS63168565A (ja) | ケトン測定方法および用具 | |
| JPH08510948A (ja) | 呼気収集装置 | |
| JPH07120463A (ja) | 呼気中の成分濃度補正方法及び呼気分析装置 | |
| Silkoff et al. | A method for the standardized offline collection of exhaled nitric oxide | |
| EP1024745A1 (fr) | Systeme de prelevement et de detection d'echantillons pour l'analyse d'haleine | |
| ES2369903T3 (es) | Método y aparato para la vertificación de la concentración intravenosa (iv) de fármacos usando aliento exhalado. | |
| JPH0658919A (ja) | 呼気分析方法及び装置 | |
| AU2006264108A1 (en) | Analysis method for determining a functional parameter of an organ using preferably an aqueous 13C methacetin solution | |
| Pincemail et al. | Pentane measurement in man as an index of lipoperoxidation | |
| JP2004077467A (ja) | 終末呼気の採取方法及び装置 | |
| JPH0647047A (ja) | 臨床用呼気検査方法及び装置 | |
| JPH10186A (ja) | 呼気中の特定ガス成分を分析する方法及び装置 | |
| JP4028006B2 (ja) | 呼気中の特定ガス成分の分析装置 | |
| Periago et al. | Design and evaluation of an exhaled breath sampler for biological monitoring of organic solvents | |
| Blom et al. | Methanethiol metabolism and its role in the pathogenesis of hepatic encephalopathy in rats and dogs |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
| 17P | Request for examination filed |
Effective date: 20000505 |
|
| AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE |
|
| A4 | Supplementary search report drawn up and despatched |
Effective date: 20010308 |
|
| AK | Designated contracting states |
Kind code of ref document: A4 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
| 18D | Application deemed to be withdrawn |
Effective date: 20030501 |